Ginkgo Bioworks Holdings, Inc.

NYSE DNA

Ginkgo Bioworks Holdings, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -95.83 M

Ginkgo Bioworks Holdings, Inc. Net Cash Used For Investing Activities is USD -95.83 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -2,139.43% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Ginkgo Bioworks Holdings, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -4.28 M, a 95.39% change year over year.
  • Ginkgo Bioworks Holdings, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -92.91 M, a 12.61% change year over year.
  • Ginkgo Bioworks Holdings, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -106.31 M.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
NYSE: DNA

Ginkgo Bioworks Holdings, Inc.

CEO Dr. Jason Kelly Ph.D.
IPO Date April 19, 2021
Location United States
Headquarters 27 Drydock Avenue
Employees 1,218
Sector Health Care
Industries
Biotechnology
Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email